Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Nvidia Develops New Location-Verification Technology for AI Chips 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SAN FRANCISCO, Aug. 15, 2017 -- NGX Bio, Inc., (www.NGXbio.com) the premier marketplace for online DNA sequencing services, announced it has closed a $3 million funding round. The round was led by 180 Degree Capital Corp. (NASDAQ:TURN) and included Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors.
NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally. Demand for sequencing services is growing exponentially. NGX Bio’s platform matches the sequencing needs of customers with providers who have available sequencing capacity. Customers are able to purchase a wide range of sequencing services for their samples using NGX Bio’s online ordering tools. NGX Bio offers these services through numerous and deep relationships with its extensive network of sequencing service providers. The ability to offer virtually unlimited sequencing capacity, to finish projects rapidly, and to always stay at the cutting edge of fast-evolving sequencing technologies distinguishes NGX Bio from its competitors and from internal corporate, academic or government sequencing resources.
“We appreciate the support from our investors to fund the next stage of the growth of our business,” said Denis Kourakin, President and Chief Executive Officer of NGX Bio. “Our platform makes completion of sequencing projects simpler and more affordable for all clients and allows them to scale without the need for capital investment. This funding will allow us to continue our relentless focus on delivering high-quality, rapid and cost-effective sequencing solutions for our customers."
About NGX Bio:
NGX Bio is a San Francisco-based company providing streamlined, on-line access to next generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing solutions globally. Founded in 2014 by two professors of Stanford University, NGX Bio offers virtually unlimited sequencing capacity to its customers through its partnerships with numerous sequencing providers.
Contact: Denis Kourakin Phone: +1 (415) 464 6379 e-mail: [email protected]
